Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.17 CAD -3.51% Market Closed
Market Cap: 307m CAD

Profound Medical Corp
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Profound Medical Corp
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Other Items
-CA$7.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Ondine Biomedical Inc
LSE:OBI
Other Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Conavi Medical Corp
XTSX:CNVI
Other Items
$3.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
81%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
307.1m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.29 CAD
Overvaluation 48%
Intrinsic Value
Price

See Also

Back to Top